Keryx Biopharmaceuticals Inc (KERX.OQ)
5 Dec 2016
* Keryx biopharmaceuticals -patheon manufacturing services llc is now an fda approved drug product manufacturer of auryxia
* Keryx Biopharmaceuticals announces third quarter 2016 financial results and provides corporate update
* Keryx Biopharmaceuticals Inc - Files for mixed shelf of up to $250 million - SEC filing Source text: [http://bit.ly/2ff1wha] Further company coverage:
BRIEF-Keryx Biopharmaceuticals and Patheon Manufacturing Services, it affiliates entered into a Master Manufacturing Services
* Keryx Biopharmaceuticals - Co, Patheon Manufacturing Services, it affiliates of entered into a Master Manufacturing Services, 2 product agreements
Keryx Biopharmaceuticals Inc withdrew its full-year forecast due to a disruption in production of its only approved drug, Auryxia, sending its shares down by more than a third in morning trading on Monday.
* Shares fall by a third (Adds analyst comment; updates shares)
* Company announces interruption in supply of Auryxia(ferric citrate)
Aug 1 Keryx Biopharmaceuticals Inc said it was withdrawing its full-year forecast due to issues related to the production of its only approved drug, Auryxia.
* Keryx biopharmaceuticals appoints two new board members Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)